Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
How to Determine if Your Clinical Trial Has Sufficient Data?
How to Use Historical Data to Mitigate Clinical Trial Risk
A Bayesian Optimal Design Advancing the Precision Medicine Approach
Use of Rolling-enrollment Designs to Accelerate Clinical Trials
Use of Bayesian Approach in Basket Trial Design
Single Arm Multi-Stage Phase 2 Cancer Trials
Introduction to Evidence Synthesis and Bayesian dynamic borrowing
Cytel Thought Leadership on Power of Bayesian Methods
The Meta-Analytic-Predictive Priors Generation and Comparisons
Frequentist? Time for an update!
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice